Biogen Idec and Elan have informed healthcare professionals of reports of “clinically significant” liver injuries among patients treated with TYSABRI (natalizumab), a drug used for treatment of multiple sclerosis (MS).
Signs of liver damage were apparent after as little as six days from the first dose. The combination of transaminase elevations and elevated billirubin without evidence of an obstruction is “generally recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant”.
If you are taking or have taken TYSABRI for any reason contact your doctor immediately to discuss these new findings and schedule a test to determine your liver values.
Tysabri is a monoclonal antibody that affects the actions of the body’s immune system. It is generally used to treat relapsing forms of multiple sclerosis, but Tysabri may also be used for other purposes.